Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/32/43/8d/32438d12-f214-2b84-a090-4cb5c1fd55ff/mza_1588204697638323759.jpg/600x600bb.jpg

Project Oncology®

ReachMD

180 episodes

3 days ago

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

Science

Medicine

RSS

All content for Project Oncology® is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study

Project Oncology®

1 month ago

Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study

Host: Marlene Mimi Maeusli, PhD.

A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.